OPCH · CIK 1014739
What Option Care Health, Inc. told the SEC could break it.
Option Care's sharpest exposure is drug-pricing policy: the Inflation Reduction Act lets CMS negotiate Medicare Part D prices, and the first round cut one therapy in its portfolio by 66% from its 2023 list price effective January 2026, with ongoing negotiations expected to keep pressuring results. Its revenue is also essentially all reimbursement-dependent — 88% from managed-care and other non-government payers and 12% from Medicare/Medicaid — with its single largest payer about 14% of 2025 revenue, so rate pressure or loss there would hurt. And it carries $1,176.3 million of outstanding borrowings (a first-lien term loan plus $500 million of 4.375% notes due 2029), which could divert cash to debt service and constrain liquidity and growth.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Regulatory & policy
- IRA Medicare Part D drug price negotiationhigh
The Inflation Reduction Act lets CMS negotiate Medicare Part D drug prices; the first round cut one therapy in Option Care's portfolio by 66% from 2023 list price effective January 2026, and ongoing IRA-mandated negotiations and CMS determinations are expected to keep pressuring results.
“In August 2024, CMS announced the results of its first round of drug price negotiations, which included a 66% reduction from 2023 list price for one therapy in our portfolio effective January 2026.”
Customer concentration
- Third-party payer concentration (largest payer 14%)medium
Essentially all revenue is reimbursement-dependent — 88% from MCOs and other non-government payers and 12% from Medicare/Medicaid — and the single largest payer accounted for about 14% of revenue in 2025 (15% in 2024), so loss of or rate pressure from that payer would materially hit results.
“Revenue related to the Company's largest payer was approximately 14 %, 15 %, and 14 % for the years ended December 31, 2025, 2024, and 2023, respectively. There were no other managed care contracts that represent greater than 10% of revenue for the years presented.”
SEC filing →As of 2026
Liquidity & debt
- Outstanding borrowings ($1.18B)medium
Carries $1,176.3 million of outstanding borrowings (a First Lien Term Loan plus $500M of 4.375% Senior Unsecured Notes due 2029) that could divert cash to debt service and constrain liquidity and growth investment.
“As of December 31, 2025, we had $1,176.3 million of outstanding borrowings”
SEC filing →As of 2026
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch